SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine

NCT04952402 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

43

Enrollment

NIH

Sponsor class

Conditions

Covid19
SARS-CoV2 Infection

Interventions

BIOLOGICAL: Study-provided Moderna mRNA-1273 COVID-19 vaccine
BIOLOGICAL: Community-provided Moderna mRNA-1273 COVID-19 Vaccine
BIOLOGICAL: Community-Provided Pfizer-BioNTech BNT162b2 COVID-19 Vaccine

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)